rs1060501105
Variant summary
Our verdict is Pathogenic. The variant received 12 ACMG points: 12P and 0B. PVS1_ModeratePM2PP5_Very_Strong
The NM_016169.4(SUFU):c.1023-2A>T variant causes a splice acceptor, intron change involving the alteration of a conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. 3/3 splice prediction tools predicting alterations to normal splicing. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_016169.4 splice_acceptor, intron
Scores
Clinical Significance
Conservation
Publications
- medulloblastomaInheritance: AD Classification: DEFINITIVE, STRONG Submitted by: Ambry Genetics, Labcorp Genetics (formerly Invitae), ClinGen
- nevoid basal cell carcinoma syndromeInheritance: AD Classification: DEFINITIVE, STRONG, SUPPORTIVE Submitted by: Orphanet, Illumina, Genomics England PanelApp
- basal cell nevus syndrome 2Inheritance: AD Classification: STRONG Submitted by: G2P
- ocular motor apraxia, Cogan typeInheritance: AD Classification: STRONG Submitted by: Franklin by Genoox
- Joubert syndrome 32Inheritance: AR Classification: STRONG, LIMITED Submitted by: Labcorp Genetics (formerly Invitae), G2P, Ambry Genetics
- Joubert syndromeInheritance: AR, AD Classification: MODERATE, SUPPORTIVE Submitted by: Orphanet, Ambry Genetics
- apraxiaInheritance: AD Classification: LIMITED Submitted by: Ambry Genetics
- ciliopathyInheritance: AR Classification: LIMITED Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Our verdict: Pathogenic. The variant received 12 ACMG points.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| SUFU | NM_016169.4 | c.1023-2A>T | splice_acceptor_variant, intron_variant | Intron 8 of 11 | ENST00000369902.8 | NP_057253.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| SUFU | ENST00000369902.8 | c.1023-2A>T | splice_acceptor_variant, intron_variant | Intron 8 of 11 | 1 | NM_016169.4 | ENSP00000358918.4 | |||
| SUFU | ENST00000423559.2 | c.1023-2A>T | splice_acceptor_variant, intron_variant | Intron 8 of 9 | 1 | ENSP00000411597.2 | ||||
| SUFU | ENST00000369899.6 | c.1023-2A>T | splice_acceptor_variant, intron_variant | Intron 8 of 10 | 1 | ENSP00000358915.2 |
Frequencies
GnomAD3 genomes Cov.: 31
GnomAD4 exome Cov.: 32
GnomAD4 genome Cov.: 31
ClinVar
Submissions by phenotype
Joubert syndrome 32;C5830451:Basal cell nevus syndrome 2 Pathogenic:1
- -
Gorlin syndrome;C0025149:Medulloblastoma Pathogenic:1
This sequence change affects an acceptor splice site in intron 8 of the SUFU gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in SUFU are known to be pathogenic (PMID: 22508808, 25403219, 33024317). This variant is not present in population databases (gnomAD no frequency). This variant has not been reported in the literature in individuals affected with SUFU-related conditions. ClinVar contains an entry for this variant (Variation ID: 406381). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at